Immutep Limited (ASX: $IMM) Quarterly Activities Report & Appendix 4C Q3 FY24

Immutep Limited (ASX: $IMM) provides an update on the ongoing development of its product candidates, eftilagimod alpha (efti) and IMP761 for the quarter ended 31 March 2024 (Q3 FY24). The Company reported positive clinical data from the safety lead-in of AIPAC-003 in metastatic breast cancer, showing a 90mg dosing of efti to be safe and well tolerated with a 50% overall response rate. Additionally, the Company announced the appointment of Anne Anderson as an independent non-executive director on Immutep's Board.

Executive Commentary

The first clinical data from the safety lead-in of AIPAC-003 in metastatic breast cancer is very encouraging. The 90mg dosing of efti has shown to be safe and well tolerated, with a 50% overall response rate, including one patient reporting a complete response, and a 100% disease control rate. We are also pleased with the progress of preclinical studies of IMP761, which are expected to advance to clinical trials mid-CY2024. Furthermore, we welcome Anne Anderson to our Board as an independent non-executive director, bringing extensive experience and capability across capital markets, risk management, and governance.

Corporate & Financial Summary

Immutep (ASX: $IMM) continues to make significant progress in its clinical trials, with positive preliminary results from the TACTI-003 trial in first line metastatic head and neck squamous cell carcinoma patients. The Company also reported encouraging data from the TACTI-002 trial in 1L NSCLC, with excellent median Overall Survival rates seen across all levels of PD-L1 expression. Additionally, the progress of preclinical studies of IMP761 is noteworthy, with plans to begin first-in-human trials mid-CY2024. Immutep remains well funded with a strong cash and cash equivalent balance, providing financial stability to support its ongoing development programs.